LEGAL GUIDES FOR CONSUMERS ON DANGEROUS DRUGS

If you suffered Onglyza Side Effects contact Nashville Onglyza lawyer Timothy L. Miles, you could be eligible for an Onglyza lawsuit

Onglyza (saxagliptin) and Kombiglyze XR (saxagliptin and metformin) belong to a new class of diabetic drugs known as DPP-4 inhibitors. Onglyza gained federal drug approval by the U.S. Food & Drug Administration (FDA) despite initial concerns over the cardiovascular safety of the drug.

These concerns were echoed in a post-marketing safety study that found Onglyza may be associated with an increased risk of heart failure and an increased risk of death.

If you or a loved one took Onglyza as directed and suffered from Onglyza side effects including heart failure or other cardiovascular injuries—such as congestive heart failure or myocardial infarction, after starting Onglyza therapy, contact Nashville Onglyza lawyer Timothy L. Miles today for a free case evaluation to see if you are eligible for an Onglyza lawsuit and possibly entitled to substantial compensation.  

​​Onglyza (saxagliptin) is an add-on medication to diet and exercise to improve blood sugar control in people with type 2 diabetes.  It is a is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases the amount of insulin your body makes. Onglyza comes in tablets in dosages of 2.5 mg and 5 mg taken once by mouth daily.

​​You should not take Onglyza if you are allergic to any of its ingredients. Serious allergic reactions can occur with Onglyza including swelling of the face, throat, lips and difficulty breathing, among others. Your doctor should test your blood to measure how well your kidneys work before and during treatment with Onglyza. You may need a lower dose of Onglyza if your kidneys are not working well.

​​​Type 2 diabetes patients have a significantly increased risk of cardiovascular complications, and the majority of diabetics die from such complications. Amid growing concerns over the safety of many diabetes drugs, in 2008 the FDA recommended that the makers of new type 2 diabetes drugs provide evidence that the drugs do not increase the risk of cardiovascular events such as heart attacks. 

Onglyza met the FDA's cardiovascular safety criteria. Though the FDA approved the new diabetic drug, it had reservations about the sufficiency of Onglyza clinical trials and ordered AstraZeneca to perform a post-marketing study. As a result, AstraZeneca completed a 16,000-patient cardiovascular outcomes trial called SAVOR. The results of that trial were published in the New England Journal of Medicine and raised major Onglyza safety concerns.

​SAVOR found that Onglyza patients were 27% more likely to be hospitalized for heart failure. The study also found a significant increase in the rate of “all-cause mortality” among Onglyza patients.
The warning signs of heart failure include:

• Shortness of breath
• Persistent cough or wheezing
• Swelling in the lower extremities or abdomen
• Fatigue
• Nausea
• Diminished appetite
• Impaired cognitive ability
• Increased heart rate

Following the release of SAVOR, the FDA issued an Onglyza drug safety communication and convened an advisory committee meeting to analyze the results and recommend further action. The committee voted 14-to-1 to add information to Onglyza’s label warning about heart failure risks. The other member voted to withdraw Onglyza from the U.S. market.

The committee, however, did not advise updating the warning label to address the measured increase in all-cause mortality among Onglyza patients and did not recommend any restrictions on prescribing the drug.

In an April 2016 drug safety communication, the FDA announced that Onglyza and Kombiglyze XR are now required to carry warnings about heart failure risk. Other FDA warnings about saxagliptin include:

• A warning about severe joint pain
• A warning about pancreatitis and pancreatic cancer

​​In addition to heart failure, Onglyza is linked to these adverse Onglyza side effects:

• Severe joint pain
• Pancreatitis
• Pancreatic cancer
• Thyroid cancer
• Severe allergic reactions
• Hypoglycemia
• Upper respiratory tract infection
• Urinary tract infection

​​If you or a loved one took Onglyza as directed and suffered suffered heart failure, death, or another serious cardiovascular injury, after starting Onglyza therapy, you may meet the requirements for an Onglyza lawsuit and possibly be entitled to substantial compensation. Call a Nashville​ Onglyza lawyer for free today who can tell you if you are eligible for an Onglyza lawsuit.

If you meet the requirements for an Onglyza lawsuit and are successful you can recover money for some of the following damages:
     • Past and future medical bills (including medication, hospital stays, and in-home care)
     • Pain and suffering
     • Lost wages
     • Loss of earning capacity
     • Funeral expenses (in the event of a loved one’s death)
 
Broadly speaking, a plaintiff who is eligible for an Onglyza lawsuit could be entitled to compensation for any past and future costs associated with their diagnosis if they meet the requirements for an Onglyza lawsuit and are successful. ​

​It does not cost anything to hire a Nashville Onglyza lawyer.  We take all cases on a contingency basis which means we do not get paid unless we win your case.  A Nashville Onglyza lawyer can explain the process and answer any questions you may have including whether you are eligible for an Onglyza lawsuit.  Call a Nashville Onglyza lawyer today for a free case evaluation.

If you or a loved one took Onglyza as directed and suffered from Onglyza Side Effects, specifically: heart failure, death or another serious cardiovascular injury —such as congestive heart failure or myocardial infarction, after starting Onglyza therapy, contact Nashville​ Onglyza lawyer Timothy L. Miles today to see if you are eligible for a Onglyza lawsuit and possibly entitled to substantial compensation. ​​

If you suffered Onglyza Side Effects contact Nashville Onglyza lawyer Timothy L. Miles, you could be eligible for an Onglyza lawsuit

Onglyza (saxagliptin) and Kombiglyze XR (saxagliptin and metformin) belong to a new class of diabetic drugs known as DPP-4 inhibitors. Onglyza gained federal drug approval by the U.S. Food & Drug Administration (FDA) despite initial concerns over the cardiovascular safety of the drug.

These concerns were echoed in a post-marketing safety study that found Onglyza may be associated with an increased risk of heart failure and an increased risk of death.

If you or a loved one took Onglyza as directed and suffered from Onglyza side effects including heart failure or other cardiovascular injuries—such as congestive heart failure or myocardial infarction, after starting Onglyza therapy, contact Nashville​ Onglyza lawyer Timothy L. Miles today for a free case evaluation to see if you are eligible for an Onglyza lawsuit and possibly entitled to substantial compensation.  

Read on for more information on who is eligible for an Onglyza lawsuit and if you suffered Onglyza side effects, see if you are eligible for an Onglyza lawsuit. 

​​Onglyza (saxagliptin) is an add-on medication to diet and exercise to improve blood sugar control in people with type 2 diabetes.  It is a is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases the amount of insulin your body makes. Onglyza comes in tablets in dosages of 2.5 mg and 5 mg taken once by mouth daily.

​​​​​Type 2 diabetes patients have a significantly increased risk of cardiovascular complications, and the majority of diabetics die from such complications. Amid growing concerns over the safety of many diabetes drugs, in 2008 the FDA recommended that the makers of new type 2 diabetes drugs provide evidence that the drugs do not increase the risk of cardiovascular events such as heart attacks. 

Onglyza met the FDA's cardiovascular safety criteria. Though the FDA approved the new diabetic drug, it had reservations about the sufficiency of Onglyza clinical trials and ordered AstraZeneca to perform a post-marketing study. As a result, AstraZeneca completed a 16,000-patient cardiovascular outcomes trial called SAVOR. The results of that trial were published in the New England Journal of Medicine and raised major Onglyza safety concerns.

​SAVOR found that Onglyza patients were 27% more likely to be hospitalized for heart failure. The study also found a significant increase in the rate of “all-cause mortality” among Onglyza patients.
The warning signs of heart failure include:

• Shortness of breath
• Persistent cough or wheezing
• Swelling in the lower extremities or abdomen
• Fatigue
• Nausea
• Diminished appetite
• Impaired cognitive ability
• Increased heart rate

Following the release of SAVOR, the FDA issued an Onglyza drug safety communication and convened an advisory committee meeting to analyze the results and recommend further action. The committee voted 14-to-1 to add information to Onglyza’s label warning about heart failure risks. The other member voted to withdraw Onglyza from the U.S. market.

The committee, however, did not advise updating the warning label to address the measured increase in all-cause mortality among Onglyza patients and did not recommend any restrictions on prescribing the drug.

In an April 2016 drug safety communication, the FDA announced that Onglyza and Kombiglyze XR are now required to carry warnings about heart failure risk. Other FDA warnings about saxagliptin include:

• A warning about severe joint pain
• A warning about pancreatitis and pancreatic cancer

​​In addition to heart failure, Onglyza is linked to these adverse Onglyza side effects:

• Severe joint pain
• Pancreatitis
• Pancreatic cancer
• Thyroid cancer
• Severe allergic reactions
• Hypoglycemia
• Upper respiratory tract infection
• Urinary tract infection

​​If you or a loved one took Onglyza as directed and suffered suffered heart failure, death, or another serious cardiovascular injury, after starting Onglyza therapy, you may meet the requirements for an Onglyza lawsuit and possibly be entitled to substantial compensation. Call a Nashville​ Onglyza lawyer for free today who can tell you if you are eligible for an Onglyza lawsuit.

If you meet the requirements for an Onglyza lawsuit and are successful you can recover money for some of the following damages:
     • Past and future medical bills (including medication, hospital stays, and in-home care)
     • Pain and suffering
     • Lost wages
     • Loss of earning capacity
     • Funeral expenses (in the event of a loved one’s death)
 
Broadly speaking, a plaintiff who is eligible for an Onglyza lawsuit could be entitled to compensation for any past and future costs associated with their diagnosis if they meet the requirements for an Onglyza lawsuit and are successful. ​

​​If you are eligible for a Onglyza lawsuit, before it is filed with the court, your Nashville Onglyza lawyer will fully explain the process and will then need to ask you a few questions concerning the circumstances of you diagnoses, how long you have been taking Onglyza and your medical history including your Onglyza side effects. 

Your Nashville Onglyza lawyer will then draft what is known as a complaint. This will be a multi-page document explaining why the defendant is responsible for your injuries and what damages (that is, compensation) you are seeking.

Once your complaint is filed with the court, your Onglyza Lawsuit officially begins. From here, it will be a lot of back and forth between your Nashville Onglyza lawyer and the attorney(s) for the defendant in an attempt to resolve the matter. The attorneys may take review documents, take depositions, issue subpoenas, hire experts, calculate damages, attend hearings, and file motions, briefs, evidence or other documents with the court during the stages of the lawsuit.

If your Onglyza lawsuit is not dismissed and a settlement cannot be reached, the case will proceed to a jury trial.

If you or a loved one took Onglyza as directed and suffered from Onglyza Side Effects, specifically: heart failure, death or another serious cardiovascular injury —such as congestive heart failure or myocardial infarction, after starting Onglyza therapy, contact Nashville​Onglyza lawyer Timothy L. Miles today to see if you are eligible for a Onglyza lawsuit and possibly entitled to substantial compensation. ​​

If you suffered Onglyza Side Effects contact Nashville Onglyza lawyer Timothy L. Miles, you could be eligible for an Onglyza lawsuit

Onglyza (saxagliptin) and Kombiglyze XR (saxagliptin and metformin) belong to a new class of diabetic drugs known as DPP-4 inhibitors. Onglyza gained federal drug approval by the U.S. Food & Drug Administration (FDA) despite initial concerns over the cardiovascular safety of the drug.

These concerns were echoed in a post-marketing safety study that found Onglyza may be associated with an increased risk of heart failure and an increased risk of death.

If you or a loved one took Onglyza as directed and suffered from Onglyza side effects including heart failure or other cardiovascular injuries—such as congestive heart failure or myocardial infarction, after starting Onglyza therapy, contact Nashville Onglyza Lawyer Timothy L. Miles today for a free case evaluation to see if you are eligible for an Onglyza lawsuit and possibly entitled to substantial compensation.  

Read on to learn four things about the Onglyza lawsuit from a Nashville Onglyza lawyer.​

​​Onglyza (saxagliptin) is an add-on medication to diet and exercise to improve blood sugar control in people with type 2 diabetes.  It is a is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases the amount of insulin your body makes. Onglyza comes in tablets in dosages of 2.5 mg and 5 mg taken once by mouth daily.

​​Type 2 diabetes patients have a significantly increased risk of cardiovascular complications, and the majority of diabetics die from such complications. Amid growing concerns over the safety of many diabetes drugs, in 2008 the FDA recommended that the makers of new type 2 diabetes drugs provide evidence that the drugs do not increase the risk of cardiovascular events such as heart attacks and additional Onglyza side effects. 

Onglyza met the FDA's cardiovascular safety criteria. Though the FDA approved the new diabetic drug, it had reservations about the sufficiency of Onglyza clinical trials and ordered AstraZeneca to perform a post-marketing study. As a result, AstraZeneca completed a 16,000-patient cardiovascular outcomes trial called SAVOR. The results of that trial were published in the New England Journal of Medicine and raised major Onglyza safety concerns over Onglyza side effects. 

​SAVOR found that Onglyza patients were 27% more likely to be hospitalized for heart failure. The study also found a significant increase in the rate of “all-cause mortality” among Onglyza patients.
The warning signs of heart failure include:

• Shortness of breath
• Persistent cough or wheezing
• Swelling in the lower extremities or abdomen
• Fatigue
• Nausea
• Diminished appetite
• Impaired cognitive ability
• Increased heart rate

Following the release of SAVOR, the FDA issued an Onglyza drug safety communication and convened an advisory committee meeting to analyze the results and recommend further action. The committee voted 14-to-1 to add information to Onglyza’s label warning about heart failure risks. The other member voted to withdraw Onglyza from the U.S. market.

The committee, however, did not advise updating the warning label to address the measured increase in all-cause mortality among Onglyza patients and did not recommend any restrictions on prescribing the drug.

In an April 2016 drug safety communication, the FDA announced that Onglyza and Kombiglyze XR are now required to carry warnings about heart failure risk as another of the Onglyza side effects.  Other FDA warnings about saxagliptin include:

• A warning about severe joint pain
• A warning about pancreatitis and pancreatic cancer

​​In addition to heart failure, Onglyza is linked to these adverse Onglyza side effects:

• Severe joint pain
• Pancreatitis
• Pancreatic cancer
• Thyroid cancer
• Severe allergic reactions
• Hypoglycemia
• Upper respiratory tract infection
• Urinary tract infection

​​If you or a loved one took Onglyza as directed and suffered suffered heart failure, death, or another serious cardiovascular injury, or another of the serious Onglyza side effects after starting Onglyza therapy, you may meet the requirements for an Onglyza lawsuit and possibly be eligible for an Onglyza lawsuit and possibly entitled to substantial compensation. Call a Nashville​ Onglyza lawyer for free today who can tell you if you are eligible for an Onglyza lawsuit.

If you meet the requirements for an Onglyza lawsuit and are successful you can recover money for some of the following damages:
     • Past and future medical bills (including medication, hospital stays, and in-home care)
     • Pain and suffering
     • Lost wages
     • Loss of earning capacity
     • Funeral expenses (in the event of a loved one’s death)
 
Broadly speaking, a plaintiff who is eligible for an Onglyza lawsuit could be entitled to compensation for any past and future costs associated with their diagnosis if they meet the requirements for an Onglyza lawsuit and are successful. ​

It does not cost anything to hire a Nashville​ Onglyza lawyer.  We take all cases on a contingency basis which means we do not get paid unless we win your case.  A Nashville​Onglyza lawyer can explain the process and answer any questions you may have including whether you are eligible for an Onglyza lawsuit.  

If you or a loved one took Onglyza as directed and suffered from Onglyza Side Effects, specifically: heart failure, death or another serious cardiovascular injury —such as congestive heart failure or myocardial infarction, after starting Onglyza therapy, contact Nashville​Onglyza lawyer Timothy L. Miles today to see if you meet the requirements for an Onglyza lawsuit and are eligible for a Onglyza lawsuit and possibly entitled to substantial compensation. ​

If you suffered Onglyza Side Effects contact Onglyza lawyer Timothy L. Miles, you could be eligible for an Onglyza lawsuit

Onglyza (saxagliptin) and Kombiglyze XR (saxagliptin and metformin) belong to a new class of diabetic drugs known as DPP-4 inhibitors. Onglyza gained federal drug approval by the U.S. Food & Drug Administration (FDA) despite initial concerns over the cardiovascular safety of the drug.

These concerns were echoed in a post-marketing safety study that found Onglyza may be associated with an increased risk of heart failure and an increased risk of death.

If you or a loved one took Onglyza as directed and suffered from Onglyza side effects including heart failure or other cardiovascular injuries—such as congestive heart failure or myocardial infarction, after starting Onglyza therapy, contact Nashville​ Onglyza lawyer Timothy L. Miles today for a free case evaluation to see if you are eligible for an Onglyza lawsuit and possibly entitled to substantial compensation.  

Read on for what you need to know about the Onglyza lawsuits by Nashville Onglyza lawyer Timothy L. Miles.

​​Onglyza (saxagliptin) is an add-on medication to diet and exercise to improve blood sugar control in people with type 2 diabetes.  It is a is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases the amount of insulin your body makes. Onglyza comes in tablets in dosages of 2.5 mg and 5 mg taken once by mouth daily.

​​​Type 2 diabetes patients have a significantly increased risk of cardiovascular complications, and the majority of diabetics die from such complications. Amid growing concerns over the safety of many diabetes drugs, in 2008 the FDA recommended that the makers of new type 2 diabetes drugs provide evidence that the drugs do not increase the risk of cardiovascular events such as heart attacks. 

Onglyza met the FDA's cardiovascular safety criteria. Though the FDA approved the new diabetic drug, it had reservations about the sufficiency of Onglyza clinical trials and ordered AstraZeneca to perform a post-marketing study. As a result, AstraZeneca completed a 16,000-patient cardiovascular outcomes trial called SAVOR. The results of that trial were published in the New England Journal of Medicine and raised major Onglyza safety concerns.

​SAVOR found that Onglyza patients were 27% more likely to be hospitalized for heart failure. The study also found a significant increase in the rate of “all-cause mortality” among Onglyza patients.
The warning signs of heart failure include:

• Shortness of breath
• Persistent cough or wheezing
• Swelling in the lower extremities or abdomen
• Fatigue
• Nausea
• Diminished appetite
• Impaired cognitive ability
• Increased heart rate

Following the release of SAVOR, the FDA issued an Onglyza drug safety communication and convened an advisory committee meeting to analyze the results and recommend further action. The committee voted 14-to-1 to add information to Onglyza’s label warning about heart failure risks. The other member voted to withdraw Onglyza from the U.S. market.

The committee, however, did not advise updating the warning label to address the measured increase in all-cause mortality among Onglyza patients and did not recommend any restrictions on prescribing the drug.

In an April 2016 drug safety communication, the FDA announced that Onglyza and Kombiglyze XR are now required to carry warnings about heart failure risk. Other FDA warnings about saxagliptin include:

• A warning about severe joint pain
• A warning about pancreatitis and pancreatic cancer

​​In addition to heart failure, Onglyza is linked to these adverse Onglyza side effects:

• Severe joint pain
• Pancreatitis
• Pancreatic cancer
• Thyroid cancer
• Severe allergic reactions
• Hypoglycemia
• Upper respiratory tract infection
• Urinary tract infection

​

​​If you or a loved one took Onglyza as directed and suffered suffered heart failure, death, or another serious cardiovascular injury,  other another of the serious Onglyza side effects after starting Onglyza therapy, you may meet the requirements for an Onglyza lawsuit and possibly be entitled to substantial compensation. Call a Nashville​ Onglyza lawyer for free today who can tell you if you are eligible for an Onglyza lawsuit.

If you meet the requirements for an Onglyza lawsuit and are successful you can recover money for some of the following damages:
     • Past and future medical bills (including medication, hospital stays, and in-home care)
     • Pain and suffering
     • Lost wages
     • Loss of earning capacity
     • Funeral expenses (in the event of a loved one’s death)
 
Broadly speaking, a plaintiff who is eligible for an Onglyza lawsuit could be entitled to compensation for any past and future costs associated with their diagnosis if they meet the requirements for an Onglyza lawsuit and are successful. 

If you or a loved one took Onglyza as directed and suffered from Onglyza Side Effects, specifically: heart failure, death or another serious cardiovascular injury —such as congestive heart failure or myocardial infarction, after starting Onglyza therapy, contact Nashville​Onglyza lawyer Timothy L. Miles today to see if you are eligible for a Onglyza lawsuit and possibly entitled to substantial compensation. ​​

If you suffered Onglyza side effects, contact a Onglyza lawyer today you could be eligible for an Onglyza lawsuit

Onglyza (saxagliptin) and Kombiglyze XR (saxagliptin and metformin) belong to a new class of diabetic drugs known as DPP-4 inhibitors. Onglyza gained federal drug approval by the U.S. Food & Drug Administration (FDA) despite initial concerns over the cardiovascular safety of the drug.

These concerns were echoed in a post-marketing safety study that found Onglyza may be associated with an increased risk of heart failure and an increased risk of death and other Onglyza side effects.

If you or a loved one took Onglyza as directed and suffered from Onglyza side effects including heart failure or other cardiovascular injuries after starting Onglyza therapy, contact Onglyza lawyer Timothy L. Miles today for a free case evaluation to see if you are eligible for an Onglyza lawsuit and possibly entitled to substantial compensation.  

Read on to learn about the Onglza side effects and if you could be eligible for an Onglyza lawsuit.

​​You should not take Onglyza if you are allergic to any of its ingredients. Serious allergic reactions can occur with Onglyza including swelling of the face, throat, lips and difficulty breathing, among others. Your doctor should test your blood to measure how well your kidneys work before and during treatment with Onglyza. You may need a lower dose of Onglyza if your kidneys are not working well.

​Type 2 diabetes patients have a significantly increased risk of cardiovascular complications, and the majority of diabetics die from such complications. Amid growing concerns over the safety of many diabetes drugs, in 2008 the FDA recommended that the makers of new type 2 diabetes drugs provide evidence that the drugs do not increase the risk of cardiovascular events such as heart attacks. 

Onglyza met the FDA's cardiovascular safety criteria. Though the FDA approved the new diabetic drug, it had reservations about the sufficiency of Onglyza clinical trials and ordered AstraZeneca to perform a post-marketing study. As a result, AstraZeneca completed a 16,000-patient cardiovascular outcomes trial called SAVOR. The results of that trial were published in the New England Journal of Medicine and raised major Onglyza safety concerns including Onglyza side effects.

​SAVOR found that Onglyza patients were 27% more likely to be hospitalized for heart failure. The study also found a significant increase in the rate of “all-cause mortality” among Onglyza patients.
The warning signs of heart failure include:

• Shortness of breath
• Persistent cough or wheezing
• Swelling in the lower extremities or abdomen
• Fatigue
• Nausea
• Diminished appetite
• Impaired cognitive ability
• Increased heart rate

Following the release of SAVOR, the FDA issued an Onglyza drug safety communication and convened an advisory committee meeting to analyze the results and recommend further action. The committee voted 14-to-1 to add information to Onglyza’s label warning about heart failure risks and other Onglyza side effects. The other member voted to withdraw Onglyza from the U.S. market.

The committee, however, did not advise updating the warning label to address the measured increase in all-cause mortality among Onglyza patients and did not recommend any restrictions on prescribing the drug.

In an April 2016 drug safety communication, the FDA announced that Onglyza and Kombiglyze XR are now required to carry warnings about heart failure risk. Other FDA warnings about saxagliptin include:

• A warning about severe joint pain
• A warning about pancreatitis and pancreatic cancer

​​In addition to heart failure, Onglyza is linked to these adverse Onglyza side effects:

• Severe joint pain
• Pancreatitis
• Pancreatic cancer
• Thyroid cancer
• Severe allergic reactions
• Hypoglycemia
• Upper respiratory tract infection
• Urinary tract infection

​​If you or a loved one took Onglyza as directed and suffered suffered heart failure, death, or another serious cardiovascular injury, or other Onglyza side effects after starting Onglyza therapy, you may meet the requirements for an Onglyza lawsuit and possibly be entitled to substantial compensation. Call an Onglyza lawyer for free today who can tell you if you are eligible for an Onglyza lawsuit.

If you meet the requirements for an Onglyza lawsuit and are successful you can recover money for some of the following damages:
     • Past and future medical bills (including medication, hospital stays, and in-home care)
     • Pain and suffering
     • Lost wages
     • Loss of earning capacity
     • Funeral expenses (in the event of a loved one’s death)
 
Broadly speaking, a plaintiff who is eligible for an Onglyza lawsuit could be entitled to compensation for any past and future costs associated with their diagnosis if they meet the requirements for an Onglyza lawsuit and are successful.